Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Clinical Trials Rare Diseases Research & Development

Will Ultragenyx/Kyowa Hypophosphatemia Data Support Uptake?

Executive Summary

Ultragenyx and partner Kyowa Hakko Kirin said burosumab (KRN23) met the primary endpoint regarding phosphate levels in a Phase III study that enrolled adult X-linked hypophosphatemia patients, but small effects on two out of three secondary endpoints could impact the product's use.

You may also be interested in...



Keeping Track: A Fresh Wave Of Approvals

The latest drug development news and highlights from our US FDA Performance Tracker.

Ultragenyx Gets Commercial Feet Wet With Mepsevii Launch In Sly Syndrome

Commercial opportunity for Mepsevii is small, but launch paves way for company's second product burosumab, following on its heels.

Keeping Track: FDA Hands Out Complete Responses, Expedited Pathway Designations

The latest US drug development news and highlights from our Performance Tracker.

Table

View full table

Related Content

Pink Sheet
Scrip
Scrip
Scrip

Topics

Related Companies

Tags:
Clinical Trials Rare Diseases Research & Development
Latest Headlines

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

Normality Reasserts Itself For Biotech IPOs

Executives On The Move: Changes At The Top At Viatris And Clinuvel Among This Week's Announcements

Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win

See All
UsernamePublicRestriction

Register

SC098588

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By